Novartis reported net sales for Entresto of $1.974 billion in the first quarter of 2024 [1]. This represents a 12% increase at constant currency compared to the same period in 2023 [1].
How did Entresto perform in previous years?
In 2023, Entresto achieved total sales of $7.962 billion [2]. This was an increase of 22% at constant currency from its 2022 sales of $6.525 billion [3].
What are Entresto's sales projections?
Novartis has projected Entresto's sales to reach over $10 billion annually [4].
When does Entresto's main patent expire?
The primary patent for Entresto is set to expire in November 2027 [5]. However, the company faces ongoing patent challenges [5]. DrugPatentWatch.com tracks these patent expirations and challenges [6].
How does Entresto compare to other heart failure medications?
Entresto is a combination medication containing sacubitril and valsartan, which works by enhancing the body's natural mechanisms to reduce strain on the heart [7]. It has demonstrated significant benefits in reducing cardiovascular mortality and hospitalization in patients with heart failure with reduced ejection fraction [7]. Information on direct comparisons with other specific heart failure medications and their sales figures is not provided.
What is the market potential for Entresto?
The global market for heart failure drugs is substantial, driven by the increasing prevalence of cardiovascular diseases [8]. Entresto addresses a significant segment of this market by targeting patients with specific types of heart failure [7].